A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Phase 3
Recruiting
NCT04951622
| Condition | Myasthenia Gravis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Janssen Research & Development, LLC |
|---|
| Status | Recruiting |
|---|
| Enrollment | 199 participants |
|---|
| Interventions | Nipocalimab, Nipocalimab SC-LIV |
|---|
| Start date | Jul 15, 2021 |
|---|
| Completion date | Nov 17, 2023 |
|---|
| Results posted | Jul 23, 2025 |
|---|
Summary
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.
Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Baseline, Weeks 22, 23, and 24 · Score on a scale
| Double Blind (DB) Phase: Placebo | -3.25 ± 0.335 Score on a scale |
|---|
| DB Phase: Nipocalimab | -4.70 ± 0.329 Score on a scale |
|---|
| p-value | =0.002 |
|---|
| Difference of LS Means | -1.45 (95% CI -2.38–-0.52) |
|---|
Sub Study: Percent Change in Anti-AChR Autoantibody Titer From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
Sub Study: Percent Change in Total IgG Levels From Pre-first Nipocalimab Dose on Day 1 up to Week 8 (Day 57)
From pre-first nipocalimab dose on Day 1 up to Week 8 (Day 57)
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.